AIM: To explore the dynamic changes of prion protein (PrPc) in the process of gastric cancer drug resistance and the role of PrPc expression in the prognosis of gastric cancer patients receiving chemotherapy. METHODS: A series of gastric cancer cell lines resistant to different concentrations of adriamycin was established, and the expression of PrPc, Bcl-2 and Bax was detected in these cells. Apoptosis was determined using Annexin V staining. Western blotting and immunohistochemistry were performed to detect the expression of PrPc in patients receiving chemotherapy and to explore the role of PrPc expression in predicting the chemosensitivity and the outcome of gastric cancer patients receiving chemotherapy. Follow-up was performed for 2 years. RESULTS: PrPc expression was increased with the increase in drug resistance. Bcl-2, together with PrPc, increased the level of anti-apoptosis of cancer cells. Increased PrPc expression predicted the enhanced level of anti-apoptosis and resistance to anticancer drugs. PrPc expression could be used as a marker for predicting the efficacy of chemotherapy and the prognosis of gastric cancer. Increased PrPc expression predicted both poor chemosensitivity and a low 2-year survival rate. Contrarily, low PrPc expression predicted favorable chemosensitivity and a relatively high 2-year survival rate. CONCLUSION: PrPc expression is associated with histological types and differentiation of gastric cancer cells; The PrPc expression level might be a valuable marker in predicting the efficacy of chemotherapy and the prognosis of gastric cancer patients receiving chemotherapy.
AIM: To explore the dynamic changes of prion protein (PrPc) in the process of gastric cancer drug resistance and the role of PrPc expression in the prognosis of gastric cancerpatients receiving chemotherapy. METHODS: A series of gastric cancer cell lines resistant to different concentrations of adriamycin was established, and the expression of PrPc, Bcl-2 and Bax was detected in these cells. Apoptosis was determined using Annexin V staining. Western blotting and immunohistochemistry were performed to detect the expression of PrPc in patients receiving chemotherapy and to explore the role of PrPc expression in predicting the chemosensitivity and the outcome of gastric cancerpatients receiving chemotherapy. Follow-up was performed for 2 years. RESULTS:PrPc expression was increased with the increase in drug resistance. Bcl-2, together with PrPc, increased the level of anti-apoptosis of cancer cells. Increased PrPc expression predicted the enhanced level of anti-apoptosis and resistance to anticancer drugs. PrPc expression could be used as a marker for predicting the efficacy of chemotherapy and the prognosis of gastric cancer. Increased PrPc expression predicted both poor chemosensitivity and a low 2-year survival rate. Contrarily, low PrPc expression predicted favorable chemosensitivity and a relatively high 2-year survival rate. CONCLUSION:PrPc expression is associated with histological types and differentiation of gastric cancer cells; The PrPc expression level might be a valuable marker in predicting the efficacy of chemotherapy and the prognosis of gastric cancerpatients receiving chemotherapy.
Entities:
Keywords:
Apoptosis; Chemotherapy; Drug resistance; Gastric cancer; Prion protein
Authors: S Sisó; B Puig; R Varea; E Vidal; C Acín; M Prinz; F Montrasio; J Badiola; A Aguzzi; M Pumarola; I Ferrer Journal: Acta Neuropathol Date: 2002-02-26 Impact factor: 17.088
Authors: Jingping Du; Yanglin Pan; Yongquan Shi; Changcun Guo; Xiaohang Jin; Li Sun; Na Liu; Taidong Qiao; Daiming Fan Journal: Int J Cancer Date: 2005-01-10 Impact factor: 7.396
Authors: Boe-Hyun Kim; Hyoung-Gon Lee; Jin-Kyu Choi; Jae-Il Kim; Eun-Kyoung Choi; Richard I Carp; Yong-Sun Kim Journal: Brain Res Mol Brain Res Date: 2004-04-29
Authors: Marc-André Déry; Julie Jodoin; Josie Ursini-Siegel; Olga Aleynikova; Cristiano Ferrario; Saima Hassan; Mark Basik; Andréa C LeBlanc Journal: Breast Cancer Res Date: 2013-03-12 Impact factor: 6.466